Homology Medicines Inc At Cell Gene Meeting on the Mesa Transcript
Hello, everybody. Very happy to present to you the progress we've made at Homology Medicines. Very happy to be here with you virtually. It's been an exciting year for us and I'm happy to share an update.
And this slide is our forward-looking statement slide. We are a public company. And if you want to check out our SEC filings, you can find them on our website.
So here at Homology, you'll find a team that's very dedicated to the mission of finding cures for rare genetic disorders. And it's something that we use as a touchstone of the company, something that motivates us all. Many of us have been in this field for 20-plus years. And now with a technology that we have here at Homology, the potential to go after cures for these diseases is extremely exciting for us and the patient community.
So really Homology's platform that we feel is highly differentiated, it's based on a family of 15 novel AAVHSCs that can do either in vivo gene transfer and gene therapy or nuclease-free gene editing. And this gives us the ability
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |